Position in NVS
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$242,759
+$10,121 QoQ
Shares Held
1,549
+1.7% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#1,226
of 1,603 holders
Holding Since
Sep 2022
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Hennion & Walsh Asset Management, Inc. holds $55,949,166 across 10 Drug Manufacturers - General names. NVS ranks #10 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
14,360 | $17,223,816 | |
| 2 | JNJ |
Johnson & Johnson
|
43,755 | $11,112,457 | |
| 3 | MRK |
Merck & Co., Inc.
|
72,515 | $9,318,177 | |
| 4 | ABBV |
AbbVie Inc.
|
23,832 | $5,997,084 | |
| 5 | GRFS |
Grifols SA
|
592,173 | $4,192,584 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
28,507 | $3,601,574 | |
| 7 | AMGN |
Amgen Inc
|
7,665 | $2,775,649 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
18,045 | $1,039,752 |
All Filings in NVS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $242,759 | 1,549 | Shares | Sole | 2026-07-08 | |
| 2026-03-31 | $232,638 | 1,523 | Shares | Sole | 2026-05-13 | |
| 2024-06-30 | $320,657 | 3,012 | Shares | Sole | 2024-07-19 | |
| 2024-03-31 | $386,242 | 3,993 | Shares | Sole | 2024-04-17 | |
| 2023-12-31 | $391,258 | 3,875 | Shares | Sole | 2024-01-10 | |
| 2023-09-30 | $393,383 | 3,862 | Shares | Sole | 2023-10-27 | |
| 2023-06-30 | $441,582 | 4,376 | Shares | Sole | 2023-08-09 | |
| 2023-03-31 | $389,068 | 4,229 | Shares | Sole | 2023-04-20 | |
| 2022-12-31 | $347,729 | 3,833 | Shares | Sole | 2023-01-12 | |
| 2022-09-30 | $226,965 | 2,986 | Shares | Sole | 2022-11-14 | |
| No filing history on record for this holder in this stock. | ||||||